Taha Salma, D'Ascenzo Fabrizio, Moretti Claudio, Omedè Pierluigi, Montefusco Antonio, Bach Richard G, Alexander Karen P, Mehran Roxana, Ariza-Solé Albert, Zoccai Giuseppe Biondi, Gaita Fiorenzo
Division of Cardiology, Department of Internal Medicine, Città Della Salute e Della Scienza Turin, Turin, Italy ; Cardiology Department, Assuit University, Assuit, Egypt.
Division of Cardiology, Department of Internal Medicine, Città Della Salute e Della Scienza Turin, Turin, Italy.
Postepy Kardiol Interwencyjnej. 2015;11(3):182-90. doi: 10.5114/pwki.2015.54011. Epub 2015 Sep 28.
Due to its negative impact on prognosis, a clear assessment of bleeding risk for patients presenting with acute coronary syndrome (ACS) remains crucial. Different risk scores have been proposed and compared, although with inconsistent results.
We performed a meta-analysis to evaluate the accuracy of different bleeding risk scores for ACS patients.
All studies externally validating risk scores for bleeding for patients presenting with ACS were included in the present review. Accuracy of risk scores for external validation cohorts to predict major bleeding in patients with ACS was the primary end point. Sensitivity analysis was performed according to clinical presentation (ST segment elevation myocardial infarction (STEMI) and non-ST segment elevation myocardial infarction (NSTEMI)).
Nine studies and 13 759 patients were included. CRUSADE, ACUITY, ACTION and GRACE were the scores externally validated. The rate of in-hospital major bleeding was 7.80% (5.5-9.2), 2.05% (1.5-3.0) being related to access and 2.70% (1.7-4.0) needing transfusions. When evaluating all ACS patients, ACTION, CRUSADE and ACUITY performed similarly (AUC 0.75: 0.72-0.79; 0.71: 0.64-0.80 and 0.71: 0.63-0.77 respectively) when compared to GRACE (0.66; 0.64-0.67, all confidence intervals 95%). When appraising only STEMI patients, all the scores performed similarly, while CRUSADE was the only one externally validated for NSTEMI. For ACTION and ACUITY, accuracy increased for radial access patients, while no differences were found for CRUSADE.
ACTION, CRUSADE and ACUITY perform similarly to predict risk of bleeding in ACS patients. The CRUSADE score is the only one externally validated for NSTEMI, while accuracy of the scores increased with radial access.
由于其对预后的负面影响,对急性冠状动脉综合征(ACS)患者的出血风险进行明确评估仍然至关重要。尽管结果不一致,但已提出并比较了不同的风险评分。
我们进行了一项荟萃分析,以评估不同出血风险评分对ACS患者的准确性。
本综述纳入了所有对ACS患者出血风险评分进行外部验证的研究。外部验证队列中风险评分预测ACS患者大出血的准确性是主要终点。根据临床表现(ST段抬高型心肌梗死(STEMI)和非ST段抬高型心肌梗死(NSTEMI))进行敏感性分析。
纳入9项研究,共13759例患者。CRUSADE、ACUITY、ACTION和GRACE评分进行了外部验证。住院期间大出血发生率为7.80%(5.5-9.2),其中2.05%(1.5-3.0)与血管通路有关,2.70%(1.7-4.0)需要输血。在评估所有ACS患者时,与GRACE(0.66;0.64-0.67,所有置信区间95%)相比,ACTION、CRUSADE和ACUITY表现相似(AUC分别为0.75:0.72-0.79;0.71:0.64-0.80和0.71:0.63-0.77)。仅评估STEMI患者时,所有评分表现相似,而CRUSADE是唯一对NSTEMI进行外部验证的评分。对于ACTION和ACUITY,桡动脉通路患者的准确性提高,而CRUSADE未发现差异。
ACTION、CRUSADE和ACUITY在预测ACS患者出血风险方面表现相似。CRUSADE评分是唯一对NSTEMI进行外部验证的评分,而桡动脉通路可提高评分的准确性。